ENZN · Enzon Pharmaceuticals, Inc.

The adoption of the Section 382 Rights Agreement represents a high-materiality corporate governance action aimed squarely at protecting the company’s tax attributes—specifically its net operating loss carryforwards (NOLs)—from erosion under Internal Revenue Code Section 382. The filing explicitly states that an 'ownership change' (broadly defined as a cumulative increase of more than 50 percentage points in aggregate ownership by 5%+ stockholders over a three-year period) would substantially limit the annual usability of NOLs and delay their timing, significantly impairing their value. To mitigate this risk, the Board instituted a rights plan with a low 4.9% trigger—lower than the statutory 5% threshold—to deter accumulation without board consent. The structure is classic 'poison pill' design: Rights trade with common stock initially, become exercisable only upon a Flip-in Event, and then deliver substantial dilution to the acquirer while granting other shareholders deeply discounted access to common equity. Critically, the plan includes robust grandfathering for pre-existing >4.9% holders—but prohibits even incremental purchases, creating a hard ceiling on ownership expansion. The Certificate of Designation (Exhibit 3.1) confirms the Series A-2 Preferred Stock’s economic and voting parity: each share carries 1,000 votes and a $30,000 liquidation preference, reinforcing the deterrent effect. Redemption at $0.01 per Right and board discretion to exempt transactions or persons provide flexibility, but the core intent—preserving NOL value for future taxable income offset—is unambiguous and directly tied to shareholder value protection. Investors should recognize this as a defensive measure signaling both material NOL assets and heightened sensitivity to ownership shifts, with implications for takeover dynamics, activist engagement, and long-term capital allocation strategy.